New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Vyome Holdings, Inc. (HIND) news

Stories the last two months, newest first

  1. Results ·

    Vyome reports a $930,325 third-quarter loss

    Vyome reported Q3 2026 net loss of $930,325, or $0.13 per share, versus $8.6 million, or $3.06 per share, a year earlier; the comparison reflects substantial prior-year merger expenses and higher weighted-average shares. Cash was $6.96 million at quarter-end. The company continued VT-1953 CMC and product development, prepared for a planned FDA Type C meeting, and is responding to an FDA request for more information on its orphan drug application.

    Reported by Business Wire

More headlines